Aim: To compare device tolerance & participant’s subjective experience wearing a surgically implanted long term glucose sensor versus conventional CGM in adults with Type 1 Diabetes.

Method: A prototype CGM (Eclipse 3 sensor, GlySens, San Diego, CA) with masked glucose data transmitted to a study iPhone was surgically inserted superficial to the rectus sheath in 8 Adults with Type 1 Diabetes (4 Female; Mean [SD] Age 56 [7]Y; BMI 25[3]). One daily fingerstick glucose calibration was required. Participants simultaneously wore a conventional TGA approved multi-Day sensor that also transmitted unblinded glucose information to the Study iPhone. The two systems were compared using a standardized 5-point Leichardt scale questionnaire completed by participants at day 1, 7 and 14 post-implantation and monthly thereafter for the duration of study participation.

Results: The investigation and comparator sensors were worn 100% and 98% percent of the time respectively over the study duration. Figure 1 summarizes the participant experience.

Conclusions: Over time there was a general trend by all participants to favour the GlySens sensor and experience over the comparator CGM.

.

graphic
View largeDownload slide

Figure 1: Participant experience over 10 months of sensor implantation.

Disclosure

L.Robinson: None. J.Tan: None. S.L.Martha: Employee; GlySens Incorporated. D.N.O'neal: None. V.R.Obeyesekere: None. H.Jones: None. Y.W.Kong: None. C.Yuan: None. K.Bertsch: Employee; GlySens. T.L.Routh: Employee; GlySens Incorporated. C.M.Sims: Stock/Shareholder; Medtronic. A.Butler: Employee; GlySens Incorporated.

© 2023 by the American Diabetes Association
2023
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.